1. Introduction {#sec1}
===============

Prostate cancer (PCa) is the most commonly diagnosed cancer among men in over one-half of the countries of the world \[[@B1]\]. PCa is also the ninth most common cause of cancer death globally. It is estimated that there will be almost 1.3 million new cases of PCa and 359,000 associated deaths worldwide in 2018 \[[@B2]\]. Because of earlier diagnosis and improved treatment, death rates for PCa have been decreasing in many countries \[[@B3]--[@B5]\]. Epidemiologic studies have revealed many risk factors for PCa progression and death \[[@B6]\], possibly linked to a more westernized lifestyle, in combination with limited access to effective treatments \[[@B5], [@B7]\].

Aspirin as nonsteroidal anti-inflammatory drug (NSAID) that is widely used for preventing recurrent cardiovascular events \[[@B8]\] has been proposed as an anticancer agent to reduce cancer morbidity and mortality \[[@B9]--[@B12]\], especially for colorectal cancer. The molecular mechanism remains unclear; most researchers believe that the anticancer effect may be mediated through antithrombotic and anti-inflammation mechanisms via blockade of cyclooxygenase- (COX-) 1 and 2 isozymes, respectively \[[@B13]\]. In human PCa, the expression of both COX-1 and COX-2 is increased, possibly playing a role in the progression of the PCa \[[@B14], [@B15]\]. Many observational studies have examined whether aspirin affected PCa survival \[[@B11], [@B16]--[@B29]\]. However, the evidence from these studies has been inconsistent.

A meta-analysis had analyzed the association between aspirin exposure and mortality risk among PCa patients with an insignificant outcome \[[@B31]\]. This analysis used data published before 2016. However, they missed some important studies and included conference abstracts; they also committed errors of data extraction and did not explain heterogeneous source. Most important, they did not investigate potential dose/duration/frequency-response associations. To further explore the association between aspirin exposure and mortality risk among PCa patients, we included the latest studies and conducted a dose/duration/frequency-response meta-analysis to quantify the association between high dose/long term/high frequency exposure of aspirin and prostate cancer-specific mortality (PCSM) risk. To the best of our knowledge, this is the first study to investigate potential dose/duration/frequency-response associations between aspirin exposure and PCSM risk.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

We followed the meta-analysis of observational studies in epidemiology (MOOSE) guidelines \[[@B32]\]. In order to systematically retrieve studies describing the association between aspirin exposure and mortality risk, we first searched PubMed and EMBASE on April 10, 2018. We repeated the literature search on October 25, 2018, to verify that our research was based on latest data. References list of included studies and reviews were also checked. The search focused on four themes of subject terms and keywords: aspirin, nonsteroidal anti-inflammatory agents, prostate neoplasms, and mortality. The detailed search strategies are shown in the supplemental material ([available here](#supplementary-material-1){ref-type="supplementary-material"}).

2.2. Study Selection {#sec2.2}
--------------------

Literature eligibility was assessed by two investigators independently; discordant conclusions were resolved through discussion and consensus. Inclusion criteria were as follows: (1) the study was a cohort study or case-control study because of higher quality of evidence-based medical evidence; (2) reviews, case reports, letters, comments, and lectures were excluded; (3) the authors reported data from an original, peer-reviewed study; and (4) the exposure interest was aspirin exposure and the outcome was death, and the investigators reported multivariate-adjusted risk estimates with 95% confidence intervals (CIs). When articles had the same data source or included multiple publications, the articles of the most informative one or with the higher quality were included.

2.3. Data Extraction {#sec2.3}
--------------------

The following information was extracted and transferred to specially designed forms from the included studies by two investigators independently: author name, publish year, study type, region, data source, age (mean age or age range), follow-up years or study period, number of participants with PCa, number of participants who died of PCa, death assessment method, aspirin assessment method, time of aspirin use, diagnostic method of PCa, T-stage of PCa, treatment of PCa, confounders adjustment, reference number, quality assessment, and corresponding risk estimates with 95% CIs on PCSM and all-cause mortality (ACM) of prediagnostic and postdiagnostic aspirin exposure. We took the highest dose of aspirin intake as the highest dose exposure. When the highest dose of aspirin was not available in the reports, we assigned the longest duration aspirin exposure as the highest dose exposure. For studies which provided a data of dose/duration/frequency-response analysis, risk estimates with 95% CIs for at least three quantitative categories of aspirin exposure were generated. If the required data was not readily available or clear from the published study, we attempted to collect relevant data by contacting the authors at least once.

We used the Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@B33]\] to evaluate the quality of include studies. For nonrandomized studies, quality assessment includes the following aspects: selection, comparability, and exposure \[[@B34]\]. Different evaluation criteria were used for the cohort and case-control studies. The score of this scale is nine points, high quality is awarded bigger than or equal to seven points, four to six points is considered moderate quality, and poor quality is awarded less than or equal to three points. Poor quality studies would be excluded in the sensitivity analysis.

2.4. Data Synthesis and Analysis {#sec2.4}
--------------------------------

We evaluated the association between aspirin exposure and mortality risk by using risk estimates. Hazard ratio (HR), relative ratio (RR), and standardized mortality ratio (SMR) values were considered reasonable approximations to odds ratio (OR) for the relatively rare outcome \[[@B35], [@B36]\]. Because studies report different exposure categories as tertiles, quartiles, and quintiles, study-specific OR for the highest dose of aspirin exposure was compared to the lowest dose of aspirin exposure. Forest plots were created to visually assess the mortality risk of the highest dose of aspirin exposure across studies. Cochrane Q statistic and the I^2^ statistic were used to test the heterogeneity across studies \[[@B37]\]. A p value \< 0.10 was considered statistically significant for the Cochrane Q statistic. For I^2^ statistic, a value \> 50% indicated a measure of heterogeneity. Pooled ORs were obtained using inverse-variance-weighted random-effects models of DerSimonian and Laird \[[@B38]\].

The method described by Greenland and Longnecker was used for the meta-analysis of the dose/duration/frequency-response association between aspirin exposure and PCSM risk \[[@B39], [@B40]\]. The method requires that the distributions of cases and controls, cumulative exposure, ORs, and 95% CIs for at least three quantitative exposure categories were known. When there were more than two studies reporting relevant data, the dose/duration/frequency-response meta-analyses were allowed. The median or mean dose/duration/frequency exposure in each category was used as the corresponding exposure. When there was no median or mean dose/duration/frequency exposure for each category in the reports, the midpoint of the upper and lower boundaries in each category was specified as average exposure. If the highest category was open ended, the midpoint of the category was set to 1.5 times the lower boundary. When the lowest category was open ended, the lower boundary was set to zero. Additionally, restricted cubic spine models with three (10, 50, and 90%) or four knots (5, 35, 65, and 95%) of the distribution of exposure were used to evaluate the potential linear or nonlinear associations between aspirin exposure and PCSM risk \[[@B41]\]. Linearity or nonlinearity relation was calculated by testing the null hypothesis that the coefficient of the second spline is equal to zero \[[@B42]\].

The impacts of study characteristics on the results were assessed by meta-regression of region, study type, number of participants, follow-up time, study quality, and mean age. Further subgroup analysis estimated the effects of region, study type, number of participants, follow-up time, study quality, mean age, adjusted for smoking, and adjusted for cardiovascular events. Remaining studies were reanalyzed following the omission of one study at a time to evaluate the stability and reliability of the results \[[@B43]\]. When the number of studies included was bigger than ten, the potential publication bias was examined by visual inspection of the funnel plot and the result of Egger regression asymmetry test \[[@B44]\].

Analyses were done with STATA version 14.1 (Stata Corp, College Station, Texas). A two-tailed p value \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

Our initial search yielded 6,687 articles, of which we identified 204 duplicate articles. 24 articles were retained for further review after screening based on titles and abstracts. After detailed examination of these 24 full-text articles, 11 articles were excluded. 1 study \[[@B45]\] was excluded because the study was a review; 7 studies \[[@B47], [@B46]--[@B52]\] were excluded because they were conference abstracts; 2 studies were excluded because the exposure interests reported were nonaspirin NSAIDs \[[@B29], [@B53]\]; 1 study was excluded because the study used the normal population as a control group \[[@B11]\]. Ultimately, 13 articles \[[@B16]--[@B28]\] were included in our meta-analysis ([Figure 1](#fig1){ref-type="fig"}).

3.2. Study Characteristics {#sec3.2}
--------------------------

The characteristics of the included 13 articles are presented in [Table 1](#tab1){ref-type="table"}. 1 article \[[@B16]\] included two studies of different data sources. Our meta-analysis included nearly 110 thousand participants with PCa, and we observed that nearly 10 thousand participants died of PCa. The participants of 9 studies \[[@B16]--[@B18], [@B21], [@B22], [@B26]--[@B28]\] were in America, and 5 \[[@B19], [@B20], [@B23]--[@B25]\] in Europe. 1 study \[[@B25]\] was designed as a case-control study; the remaining studies were designed as cohort studies. All the studies were published in or after 2012. 10 studies \[[@B16], [@B17], [@B19]--[@B21], [@B24]--[@B27]\] were graded as having high quality, and the remainder were of moderate quality; no study was evaluated as poor quality. The follow-up duration of cohort studies ranged from 3.25 to 9.3 years. The aspirin exposure assessment method was based on self-report in 6 studies \[[@B16], [@B22], [@B26]--[@B28]\], questionnaires in 2 studies \[[@B17], [@B21]\], and prescriptions in 5 studies \[[@B19], [@B20], [@B23]--[@B25]\]. The PCa death assessment method in most studies was based on death certificates. Diagnostic method of PCa was based on clinical or/and pathologic information in 8 studies \[[@B20]--[@B24], [@B26]--[@B28]\], medical records in 4 studies \[[@B16], [@B17], [@B19]\], and international statistical classification of diseases (ICD) codes in 1 study \[[@B25]\].

3.3. The Highest Dose of Aspirin Exposure and Mortality Risk {#sec3.3}
------------------------------------------------------------

8 studies \[[@B16], [@B17], [@B19]--[@B21], [@B24], [@B25]\] examined prediagnostic aspirin exposure and 13 studies \[[@B16]--[@B23], [@B25]--[@B28]\] examined postdiagnostic aspirin exposure in relation to PCSM risk. 4 studies \[[@B16], [@B17], [@B20]\] examined prediagnostic aspirin exposure and 5 studies \[[@B16], [@B17], [@B20], [@B25]\] examined postdiagnostic aspirin exposure in relation to ACM risk. The outcome of prediagnostic aspirin exposure reported by Downer et al. \[[@B17]\] was excluded because they used the normal population as a control group. For ORs of the highest dose of aspirin exposure on PCSM, 1 study \[[@B24]\] reported a negative association of prediagnostic aspirin exposure, 1 study \[[@B20]\] reported a positive association of postdiagnostic aspirin exposure, and 2 studies \[[@B17], [@B28]\] reported a negative association of postdiagnostic aspirin exposure; the remaining studies reported that the ORs were not statistically different than 1.00. For ORs of the highest dose of aspirin exposure on ACM risk among PCa patients, 2 studies \[[@B16], [@B17]\] reported a negative association of postdiagnostic aspirin exposure and 2 studies \[[@B20], [@B25]\] reported a positive association of postdiagnostic aspirin exposure; the remaining studies reported that the ORs were not statistically different than 1.00.

In the random-effects model, the pooled OR (95% CI) of the PCSM risk of prediagnostic aspirin exposure was 0.96(95% CI: 0.87-1. 07, [Figure 2](#fig2){ref-type="fig"}); the pooled OR (95% CI) of the PCSM risk of postdiagnostic aspirin exposure was 0.92(95% CI: 0.77-1. 10, [Figure 2](#fig2){ref-type="fig"}). We found an obvious heterogeneity (I^2^ =56.9%; p =0.006) in terms of outcome of postdiagnostic aspirin exposure. For ACM risk, the pooled OR (95% CI) of prediagnostic aspirin exposure from random-effects model was 0.96(95% CI: 0.88-1. 04, [Figure 3](#fig3){ref-type="fig"}); the pooled OR (95% CI) of postdiagnostic aspirin exposure from random-effects model was 0.95(95% CI: 0.73-1. 23, [Figure 3](#fig3){ref-type="fig"}). We also detected substantial heterogeneity (I^2^=88.9%; p≤0.001) in terms of outcome of postdiagnostic aspirin exposure.

For PCSM risk, we detected a substantial heterogeneity of postdiagnostic aspirin exposure. To ascertain the heterogeneity of sources, we conducted a meta-regression analysis and the results were shown in the supplemental material. However, the results did not detect the source of the heterogeneity. Subgroup analyses were conducted by region, study type, number of participants, follow-up time, study quality, mean age, adjusted for smoking, and adjusted for cardiovascular events ([Table 2](#tab2){ref-type="table"}). The subgroup of region (America: I^2^ =48.1%, 0R: 0.81, 95% CI: 0.65-1.03), participants (\<5000: I^2^ =41.7%, 0R: 0.91, 95% CI: 0.74-1.11), age (\<=68: I^2^ =0%, 0R: 0.51, 95% CI: 0.32-0.80), follow-up time (\<=5: I^2^ =0%, 0R: 0.89, 95% CI: 0.76-1.05), quality (high: I^2^ =49.5%, 0R: 1.01, 95% CI: 0.84-1.21), adjusted for smoking (no: I^2^ =31.3%, 0R: 0.97, 95% CI: 0.79-1.18), and adjusted for cardiovascular events (no: I^2^ =37.4%, 0R: 0.96, 95% CI: 0.78-1.19) exhibited a decreases in heterogeneity. To further explore the sources of the heterogeneity, we performed the sensitivity analysis and found that the study by Assayag et al. was a major source of heterogeneity (from 42.1% to 56.9%). We omitted this study and performed the analysis again; the result remained insignificant (OR: 0.88, 95% CI: 0.75-1.05). The results of meta-regression and subgroup analyses did not indicate the source of heterogeneity, but the sensitivity analysis showed significant decreases of heterogeneity after excluding the study of Assayag et al. We found that the study of Assayag et al. reported the only positive result of PCSM risk on postdiagnostic aspirin exposure. Therefore, we speculated that the heterogeneity might derive from the study reported by Assayag et al. We found that the subgroup of less than or equal to 68 years old showed a significant negative association. Aspirin might have a little protective effect on younger patients with PCa. This result needed to be further verified because there were only 4 studies included. There was no publication bias according to the visual inspection of the funnel plot of prediagnostic aspirin exposure ([Figure 4(a)](#fig4){ref-type="fig"}) and postdiagnostic aspirin exposure ([Figure 4(b)](#fig4){ref-type="fig"}). The result of Egger\'s test of prediagnostic aspirin exposure (p = 0.276) and postdiagnostic aspirin exposure (p = 0.078) also showed no publication bias.

For ACM risk, we also detected substantial heterogeneity of postdiagnostic aspirin exposure. The sensitivity analysis of omitting one study at a time showed no substantial change in terms of results and heterogeneity. Because of the low number of studies that reported the aspirin exposure and ACM risk, subgroup and publication bias analyses were not pursued. Further studies are warranted.

3.4. Dose/Duration/Frequency-Response Meta-Analysis {#sec3.4}
---------------------------------------------------

For PCSM risk, 3 studies \[[@B21], [@B25], [@B27]\] examined dose of postdiagnostic aspirin exposure, 3 studies \[[@B17], [@B19], [@B20]\] examined duration of postdiagnostic aspirin exposure, and 3 studies \[[@B16], [@B21]\] examined frequency of both prediagnostic and postdiagnostic aspirin exposure. Every study contained relevant risk estimates with information for each exposure category reported. All studies were included in our meta-analysis. Because of a lack of data, we did not conduct a dose/duration/frequency-response meta-analysis on associations between aspirin exposure and ACM risk.

In the analysis of association between dose of postdiagnostic aspirin exposure and PCSM risk, we did not detect substantial heterogeneity (Q = 5.18, p =0.3937) and found a linearity association (p =0.7017). However, the result was not significant ([Figure 5(a)](#fig5){ref-type="fig"}). In the analysis of association between duration of postdiagnostic aspirin exposure and PCSM risk. We did not detect substantial heterogeneity (Q = 40.94, p ≤0.001) and found a nonlinearity association (p ≤0.001). The combined ORs of PCSM risk for 1.5, 2.5, and 3 years of duration exposure were 1.36 (95% CI: 1.19-1.55), 1.13 (95% CI: 0.99-1.29), and 1.04 (95% CI: 0.90-1.21), respectively ([Figure 5(b)](#fig5){ref-type="fig"}). Short-term aspirin exposure (shorter than 2.5 years) increased the risk of PCSM. The result needs to be further because of the limited number studies included. In the analysis of the association between frequency of prediagnostic aspirin exposure and PCSM risk, we did not detect substantial heterogeneity (Q = 1.89, p =0.7553) and found a linearity association (p =0.7956). The result was not significant ([Figure 5(c)](#fig5){ref-type="fig"}). In the analysis of association between frequency of postdiagnostic aspirin exposure and PCSM risk, we also did not detect substantial heterogeneity (Q = 2.07, p = 0.5327) and found a linearity association (p =0.5327). And the result was still not significant ([Figure 5(d)](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Many studies had investigated prediagnostic and postdiagnostic aspirin exposure with respect to mortality risk among PCa patients, with inconsistent results. The meta-analysis reported by Thakker et al. \[[@B31]\] had analyzed the association between aspirin exposure and mortality risk; they used the data published before 2016 and showed an insignificant outcome with substantial heterogeneity. They concluded that aspirin exposure was not associated with ACM and PCSM. However, they missed some important studies and included conference abstracts; they committed errors in data extraction and did not explain heterogeneous sources. Most important, they did not investigate potential dose/duration/frequency-response associations. The effect could have significant implications with respect to dose, frequency, and duration of aspirin use. To further explore the association between aspirin exposure and mortality risk, we updated the analysis and conducted a dose/duration/frequency-response meta-analysis to quantify the association between high dose/long term/high frequency exposure of aspirin and PCSM risk.

In this meta-analysis of 110,000 participants, we did not detect an association between the highest aspirin exposure and PCSM risk or any association regarding the highest aspirin exposure and ACM risk. The pooled ORs for PCSM of the highest postdiagnostic aspirin exposure were consistent in case-control and cohort studies. There was no significant dose-response association for dose of postdiagnostic aspirin exposure and PCSM risk. There was no significant frequency-response association for frequency of prediagnostic and postdiagnostic aspirin exposure and PCSM risk. In the meta-analysis of duration-response association, we found a nonlinearity association between duration of postdiagnostic aspirin exposure and PCSM risk. The result implied that short-term aspirin exposure (shorter than 2.5 years) increased the risk of PCSM. Indeed, premature discontinuation of drugs might mean disease progression; healthier men may continue to take aspirin. Androgen deprivation therapy had been associated with an increased risk of cardiovascular events \[[@B54], [@B55]\]. Health-conscious men with better prognosis might take aspirin earlier and longer for primary prevention. However, patients with chronic cardiovascular disease were more likely to be those long-term users of aspirin. The results require further verification for small studies. We did not conduct dose/duration/frequency-response meta-analysis of aspirin exposure and ACM risk because of lack of data. In the subgroup analysis, we found the subgroup of less than or equal to 68 years old had a significant negative association. Aspirin might have a small protective effect on younger patients with PCa, though age itself was a protective factor. This result needs to be further verified because there were only 4 studies included.

Whether aspirin protects against lethality of PCa is largely unknown. However, there have been various proposed mechanisms by which aspirin may improve oncologic outcomes. In colorectal cancer, clinical studies demonstrated that aspirin intake was associated with long-term incidence and mortality \[[@B56], [@B57]\]. Scholars who support this protective effect believe that platelets play a role in PCa metastasis by inducing angiogenesis, protecting tumor cells from immune surveillance, and promoting interactions between tumor cells and blood vessels \[[@B58]--[@B60]\]. Therefore, the antithrombotic effect of COX-1 inhibition of aspirin may impair PCa metastasis. The blockade of COX-2 could inhibit inflammation, suppress angiogenesis, and retain antimetastasis markers \[[@B61], [@B62]\]. The inhibition of COX-2 has inhibited PCa growth in both preclinical and human studies \[[@B63], [@B64]\]. Expression of both COX-1 and COX-2 was associated with increase in PCa \[[@B14], [@B15]\]. There are also COX-independent mechanisms that have been reported. However, the outcomes of our study did not accord with this view. Relative to inhibition of COX-1, aspirin has less potent COX-2 inhibitory action \[[@B65]\]. However, evidence reported recently is more likely to support the antitumor effect of COX-2 blockade \[[@B62], [@B66]--[@B68]\]. Therefore, a potent and selective inhibitor of COX-2 might represent an opportunity to augment current therapies. This is particularly of interest to patients with pain or undergoing radiation therapy where inflammation is a common side-effect. Further studies of selective inhibitors of COX-2 are needed.

Nevertheless, several limitations of our study should be acknowledged. First, this was a meta-analysis of observational studies; we could at best demonstrate an association but not a causal relationship. Second, heterogeneity was a potential problem when interpreting the results of our analysis. In analysis of PCSM risk and the highest postdiagnostic aspirin exposure, we found substantial heterogeneity, and we found the study by Assayag et al. was a major source of heterogeneity. The result remained insignificant after excluding this study. Third, the summary results might be influenced by the conversion of other measures to OR. Finally, the studies included in the dose/duration/frequency-response meta-analysis were limited; further studies are needed.

Our study also had several strengths: we performed a comprehensive systematic search for eligible studies; we conducted a dose/duration/frequency-response meta-analysis to quantify the association between high dose/long term/high frequency exposure of aspirin and PCSM risk; it was the first study to investigate potential dose/duration/frequency-response associations between aspirin exposure and PCSM risk; we included large enough numbers of participants; there was less possibility of publication bias; no substantial change in the results was found in the sensitivity analysis.

5. Conclusions {#sec5}
==============

Our meta-analysis indicates that there is no association between aspirin exposure and PCSM risk. No association was found between highest aspirin exposure and ACM risk among PCa patients. More studies are needed to develop a further dose/duration/frequency-response meta-analysis.
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*S1*: search strategies in PubMed and EMBASE.*S2*: meta-regression of the highest postdiagnostic aspirin exposure and prostate cancer-specific mortality risk.

###### 

Click here for additional data file.

![Flow diagram of systematic review of literature about aspirin exposure and mortality risk among prostate cancer patients.](BMRI2019-9379602.001){#fig1}

![*Forest plots of aspirin exposure and prostate cancer-specific mortality risk*. (The squares and horizontal lines correspond to the study-specific OR and 95% CIs. The area of the squares reflects the study-specific weight. Weights are from random-effects analysis. The diamond represents the pooled OR and 95% CI.)](BMRI2019-9379602.002){#fig2}

![*Forest plots of aspirin exposure and all-cause mortality risk among prostate cancer patients*. (The squares and horizontal lines correspond to the study-specific OR and 95% CIs. The area of the squares reflects the study-specific weight. Weights are from random-effects analysis. The diamond represents the pooled OR and 95% CI.)](BMRI2019-9379602.003){#fig3}

![*Funnel plots for publication bias on the relationship between prostate cancer-specific mortality risk and prediagnostic aspirin exposure (a) and postdiagnostic aspirin exposure (b)*. (Circles represent identified studies.)](BMRI2019-9379602.004){#fig4}

![*(a) Dose-response relationship between postdiagnostic aspirin exposure and prostate cancer-specific mortality risk; (b) duration-response relationship between postdiagnostic aspirin exposure and prostate cancer-specific mortality risk; (c) frequency-response relationship between prediagnostic aspirin exposure and prostate cancer-specific mortality risk; (d) frequency-response relationship between postdiagnostic aspirin exposure and prostate cancer-specific mortality risk*. (The solid lines represent the linear/nonlinear trend. The dashed lines dashes represent the pointwise 95% confidence intervals for the linear trend.)](BMRI2019-9379602.005){#fig5}

###### 

Characteristics of studies included in the meta-analysis of aspirin exposure and mortality risk among prostate cancer patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, year               Study type             region    Data source                                                              age     Follow-up time   Participants of PCa   Death of PCa   Death assessment                                                                  Aspirin assessment                                              use of aspirin                     Diagnosis of PCa                        T-stage of PCa         Treatment of PCa                                 Confounders adjustment                                                                                                                                                                                                                                                                                                 Reference\   OR of the highest dose exposure   Pattern score and OR           Quality assessment
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                number                                                                        
  ------------------------- ---------------------- --------- ------------------------------------------------------------------------ ------- ---------------- --------------------- -------------- --------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------- --------------------------------------- ---------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ --------------------------------- ------------------------------ ------------------------------------------
  Choe et al,\              retrospective cohort   US        CaPSURE                                                                  64      5.8              5955                  193            death certificates, National Death Index and other sources                        self-report                                                     Post-diagnosis                     clinical and pathologic information     I-IV                   RT, RT+ADT, RP                                   NA                                                                                                                                                                                                                                                                                                                     35           Post:\                            NA                             Selection: 3\
  2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.43(0.21,0.87)                                                  Comparability: 1\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Outcome: 2

  Dhillon et al,\           retrospective cohort   US        the Health Professionals Follow-up Study                                 68.6    8.4              3986                  265            National Death Index, postal system, and next\                                    self-report                                                     Post-diagnosis                     medical records and pathology reports   I-IIIa                 PT, RT, Hormone, Watchful waiting, Others        age, period, family history, race, height, BMI, tomato sauce, vigorous physical activity, smoking, vitamin D, fish, red meat, CLD, total kcal, Gleason score, aspirin use before diagnosis, TNM stage, initial treatment                                                                                               23           Post:\                            Dose:\                         Selection: 3\
  2012                                                                                                                                                                                              of kin with virtually complete follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1.08(0.76,1.54)                   Quartile 1: 1.0\               Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Quartile 2: 1.12(0.72-1.72)\   Outcome: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Quartile 3: 1.05(0.62-1.80)\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Quartile 4: 1.08(0.76-1.54)    

  Flahavan et al,\          retrospective cohort   Ireland   NCRI and GMS                                                             50-80   5.5              2936                  276            death certificates                                                                prescriptions                                                   Pre-diagnosis                      pathologic information, ICD code        I--III                 RP, PT, RT, ADT\                                 age at diagnosis, tumor grade, tumor size, smoking status, co-morbidity score, year of incidence, pre-diagnostic statin exposure and receipt of radiation                                                                                                                                                              20           Pre:\                             NA                             Selection: 3\
  2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.61(0.37,0.99)                                                  Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Outcome: 2

  Grytli et al,\            retrospective cohort   Norway    the Cancer Registry of Norway and the Norwegian Prescriptions Database   76.3    3.25             3165                  NA             death certificates                                                                prescriptions                                                   Post-diagnosis                     clinical and pathologic information     I-IV                   ADT                                              age, PSA, Gleason score, T-stage, presence and type of metastases, performance status, and ADT initiated within 6 months after diagnosis                                                                                                                                                                               27           Post:\                            NA                             Selection: 3\
  2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.94(0.78,1.14)                                                  Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Outcome: 1

  Jacobs et al,\            retrospective cohort   US        the University of Texas Southwestern Medical Center                      68      4.7              74                    15             NA                                                                                self-report                                                     Post-diagnosis                     clinical and pathologic information     Ic-IIIb, unknown       RT, ADT                                          age, Gleason score, T-stage, pelvic irradiation,\                                                                                                                                                                                                                                                                      24           Post:\                            NA                             Selection: 2\
  2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ADT, N-stage, aspirin use                                                                                                                                                                                                                                                                                                           0.44(0.15,1.28)                                                  Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Outcome: 1

  Caon et al,\              retrospective cohort   Canada    BCCA                                                                     70.3    8.4              3851                  1098           death registry records                                                            referring physician notes,\                                     Post-diagnosis                     pathologic information                  I-IV                   RT                                               statin use, ASA use, age, ADT, PSA, T-stage, Charlson index,\                                                                                                                                                                                                                                                          35           Post:\                            NA                             Selection: 3\
  2014                                                                                                                                                                                                                                                                                consultation reports,\                                                                                                                                                                                             Gleason score                                                                                                                                                                                                                                                                                                                       0.91(0.65,1.28)                                                  Comparability: 2\
                                                                                                                                                                                                                                                                                      self-report                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Outcome: 2

  Jacobs et al,\            retrospective cohort   US        CPS-II Nutrition Cohort                                                  NA      Pre: 9.3\        Pre: 8427\            Pre: 441\      National Death Index                                                              questionnaires                                                  Pre-diagnosis and Post-diagnosis   clinical and pathologic information     I-IV                   PT, RT, Cryosurgery, Hormone, Watchful waiting   age, race, calendar year of diagnosis, tumor extent, nodal involvement, Gleason score, initial treatment type, CLD, CVD, and pre-diagnosis PSA testing not leading to a PCa diagnosis.                                                                                                                                 19           Pre:\                             Dose:\                         Selection: 3\
  2014                                                                                                                                        Post: 6.4        Post: 7118            Post: 301                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.93(0.72,1.21)\                  Tertile 1: 1.00\               Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Post:\                            Tertile 2: 0.85(0.61-1.19)\    Outcome: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1.14(0.82,1.60)                   Tertile 3: 1.14(0.82-1.60)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Frequency(pre):\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 1: 1.00\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 2: 1.03(0.81-1.32)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 3: 0.92(0.72-1.17)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Frequency(post):\              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 1: 1.00\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 2: 1.12(0.81-1.53)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 3: 0.98(0.74-1.29)     

  Cardwell et al,\          case--control          UK        NCDR, CPRD                                                               NA      1998-2011        Pre: 5459\            Pre: 1371\     ONS death certificates                                                            prescriptions                                                   Pre-diagnosis and Post-diagnosis   ICD code                                I-IV                   RP, RT, CT, ADT, EST                             grade, RP,\                                                                                                                                                                                                                                                                                                            34           Pre:\                             Dose:\                         Selection: 3\
  2014                                                                                                                                                         Post: 4715            Post: 1184                                                                                                                                                                                                                                                                                                          CT, RT, ADT, EST, comorbidities and smoking                                                                                                                                                                                                                                                                                         1.11(0.83,1.49\                   Quartile 1: 1.0\               Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Post:\                            Quartile 2: 1.12(0.79-1.60)\   Outcome: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1.31(0.85,2.01)                   Quartile 3: 0.82(0.58-1.17)\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Quartile 4: 1.31(0.85-2.01)    

  Veitonmaki et al,\        retrospective cohort   Finland   FinPCST                                                                  68      7.5              Pre: 6537\            Pre: 617\      death certificates                                                                prescriptions                                                   Pre-diagnosis and Post-diagnosis   medical records                         I-IV                   PT, RT, Hormone, Watchful waiting                age, PCa stage and grade, type of treatment,\                                                                                                                                                                                                                                                                          23           Pre:\                             Duration:\                     Selection: 3\
  2015                                                                                                                                                         Post: 6537            Post: 617                                                                                                                                                                                                                                                                                                           CLD, anti-HPN drug, BPH drug and antidiabetic drug, use of NSAIDs before trial, other types of NSAIDs, PSA, cancer grade and stage.                                                                                                                                                                                                 0.93(0.53,1.63)\                  Tertile 1: 1.00\               Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Post:\                            Tertile 2: 0.54(0.27-1.10)\    Outcome: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             0.81(0.38,1.81)                   Tertile 3: 0.31(0.12-0.78)     

  Assayag et al,\           retrospective cohort   UK        the NCDR, CPRD, HES                                                      71.3    5.4              Pre: NA\              Pre: NA\       ONS death certificates                                                            prescriptions                                                   Pre-diagnosis and Post-diagnosis   clinical information, ICD code          I-IV                   PT, RT ADT, CT                                   age, year of entry, race, obesity, smoking status, alcohol use, socioeconomic status, anti-HPN drug, cardiovascular comorbidities, statins, aspirin, other APD, NSAIDs, 5a-reductase inhibitors, metformin, sulfonylureas, insulin, OADs, PSA, Gleason score and cancer treatments during first year after diagnosis   23           Pre:\                             Duration:\                     Selection: 3\
  2015                                                                                                                                                         Post: 11779           Post: 1793                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              0.97(0.81,1.16)\                  Quintile 1: 1.0\               Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Post:\                            Quintile 2: 1.61(1.40-1.84)\   Outcome: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1.32(1.06,1.64)                   Quintile 3: 1.33(1.10-1.60)\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Quintile 4: 1.06(0.83-1.37)\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Quintile 5: 1.32(1.06-1.64)    

  Osborn et al,\            retrospective cohort   US        the New York Harbor Department of Veterans Affairs                       68      6.3              289                   8              NA                                                                                physician documentation, the electronic medical record system   Post-diagnosis                     NA                                      undergoing radiation   ADT, RT                                          age, ASA use, ADT, RT, clopidogrel or warfarin usage, NCCN risk group                                                                                                                                                                                                                                                  20           Post:\                            NA                             Selection: 2\
  2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.20(0.04,1.13)                                                  Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Outcome: 2

  Downer et al,\            retrospective cohort   US        the Physicians\' Health Study                                            71.5    NA               3277                  407            death certificates, National Death Index, medical records and information from\   questionnaires                                                  Pre-diagnosis and Post-diagnosis   self-reports and medical records        I-IV                   RP, RT, others                                   age, calendar year of diagnosis, race, Charlson comorbidity index, BMI, smoking status, PSA, Gleason score, clinical stage, and primary treatment                                                                                                                                                                      28           Post\                             Duration:\                     Selection: 3\
  2017                                                                                                                                                                                              family                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   0.66(0.46,0.95)                   Tertile 1: 1.00\               Comparability: 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 2: 0.70(0.50-0.97)\    Outcome: 2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 3: 0.66(0.46-0.95)     

  Zhou \[[@B16]\] et al,\   retrospective cohort   US        NIH-AARP Diet and Health Study                                           \>=55   Pre: 6\          Pre: 19063\           Pre:709\       National Death Index                                                              self-report                                                     Pre-diagnosis and Post-diagnosis   medical records                         I-IV                   PT, RT, Hormone, RT+ Hormone                     Gleason score, tumor stage, primary treatment, race, marital status, CVD, diabetes, BMI, smoking status, PCa screening, self-reported general health status, pre-diagnostic aspirin or non-aspirin NSAID use                                                                                                           30           Pre:\                             Frequency(pre):\               Selection: 3 Comparability: 2 Outcome: 2
  2017                                                                                                                                        Post: 4          Post: 7574            Post:209                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                0.99(0.80,1.22)\                  Tertile 1: 1.00\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Post:\                            Tertile 2: 0.95(0.78-1.15)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             0.77(0.54,1.11)                   Tertile 3: 0.99(0.80-1.22)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Frequency(post):\              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 1: 1.00\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 2: 0.87(0.60-1.27)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 3: 0.77(0.54-1.11)     

  Zhou \[[@B47]\] et al,\   retrospective cohort   US        PLCO Cancer Screening Trial                                              \>=55   Pre: 5\          Pre: 7827\            Pre:266\       death certificates                                                                self-report                                                     Pre-diagnosis and Post-diagnosis   medical records                         I-IV                   PT, RT, Hormone, RT+ Hormone                     Gleason score, tumor stage, primary treatment, race, marital status, CVD, diabetes, BMI, smoking status, PCa screening, self-reported general health status, pre-diagnostic aspirin or non-aspirin NSAID use                                                                                                           30           Pre:\                             Frequency(pre):\               Selection: 3 Comparability: 2 Outcome: 2
  2017                                                                                                                                        Post: 5          Post: 4012            Post:35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.98(0.72,1.32)\                  Tertile 1: 1.00\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Post:\                            Tertile 2: 1.15(0.85-1.55)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1.26(0.43,3.67)                   Tertile 3: 0.98(0.72-1.32)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Frequency(post):\              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 1: 1.00\               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 2: 1.52(0.53-4.33)\    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tertile 3: 1.26(0.43-3.67)     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PCa: prostate cancer; USDA: the United States Department of Agriculture; ATBC: Alpha-Tocopherol Beta-Carotene Cancer Prevention Study; BLSA: Baltimore Longitudinal Study of Aging; WNYDS: Western New York Diet Study; NECSS: National Enhanced Cancer Surveillance System; PLCO: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; MDC: Malmo Diet and Cancer; EECC: Environmental Epidemiology of Cancer in Cordoba; DVAMC: Durham Veterans Affairs Medical Center; FHS: Framingham Heart Study; EPIC: European Prospective Investigation into Cancer and Nutrition; NSHD: National Survey of Health and Development; ProtecT: Prostate testing for cancer and Treatment; FFQ: food frequency questionnaire; ICD: international statistical classification of diseases; BMI: body mass index; PSA: prostate-specific antigen.

###### 

Subgroup analyses of the highest post-diagnostic aspirin exposure and prostate cancer-specific mortality risk.

  Group                                OR(95%CI)         Number of studies   I^2^ (%)   P~(heterogeneity)~
  ------------------------------------ ----------------- ------------------- ---------- --------------------
  Region                                                                                 
   America                             0.81(0.65,1.03)   9                   48.1       0.052
   Europe                              1.12(0.88,1.41)   4                   54.1       0.088
                                                                                        
  Study type                                                                             
   case-control                        1.31(0.85,2.01)   1                   NA         NA
   cohort                              0.89(0.74,1.07)   12                  57.8       0.006
                                                                                        
  Participants                                                                           
                                       0.91(0.74,1.11)   8                   41.7       0.100
                                       0.92(0.65,1.28)   5                   70.8       0.008
                                                                                        
  Age                                                                                    
                                       0.51(0.32,0.80)   4                   0          0.417
                                       0.98(0.79,1.21)   5                   67         0.017
                                                                                        
  Follow-up time                                                                         
                                       0.89(0.76,1.05)   4                   0          0.392
                                       0.96(0.74,1.24)   7                   60.5       0.019
                                                                                        
  Quality^*∗*^                                                                           
   moderate                            0.55(0.29,1.05)   4                   66.4       0.030
   high                                1.01(0.84,1.21)   9                   49.5       0.045
                                                                                        
  Adjusted for smoking                                                                   
   yes                                 0.96(0.71,1.31)   5                   70.3       0.009
   no                                  0.97(0.79,1.18)   7                   31.3       0.189
                                                                                        
  Adjusted for cardiovascular events                                                     
   yes                                 0.96(0.72,1.27)   6                   64.6       0.015
   no                                  0.96(0.78,1.19)   6                   37.4       0.157

^*∗*^A total score of 4-6 was considered moderate quality, and 7-9 was deemed high quality.

[^1]: Academic Editor: Robert J. Lee
